Download PDF
Semin Vasc Med 2005; 5(2): 190-200
DOI: 10.1055/s-2005-872404
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001 USA.

Homocysteine and Folic Acid: Implications for Pregnancy

Sean Daly1 , Amanda Cotter2 , Ann E. Molloy3 , John Scott3
  • 1Coombe Women’s Hospital, Dublin, Ireland
  • 2Department of Obstetrics and Gynecology, University of Miami, Miami, Florida
  • 3Department of Biochemistry, Trinity College Dublin, Dublin, Ireland
Further Information

Publication History

Publication Date:
27 July 2005 (online)

    Permissions and Reprints

ABSTRACT

The role of folic acid and homocysteine in pregnancy is becoming clearer. The efforts of many countries to prevent neural tube defects through public awareness of folic acid have been disappointing, but evidence is now emerging that the food fortification programs in the United States and Canada are effective in reducing the numbers of neural tube defects, and there may be additional benefits in terms of other congenital defects such as oral-facial clefts and congenital heart disease. Homocysteine has a significant association with vascular disease in later life, is elevated in preeclampsia, and has been associated with other pregnancy complications such as early pregnancy loss. The data from cohorts of women with a history of preeclampsia during pregnancy indicate that they are at increased risk for cardiovascular and cerebrovascular disease in later life. Elevated homocysteine concentrations may be a common link that accounts for these associations.

KEYWORDS

Homocysteine - folic acid - pregnancy

REFERENCES

  • 1 Kelly P, McPartlin J, Goggins M, Weir D G, Scott J M. Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements.  Am J Clin Nutr. 1997;  65 1790-1795
    PubMedGoogle Scholar
  • 2 Frosst P, Blom H J, Milos R et al.. A candidate genetic risk factor for vascular disease: A common mutation in methylene-tetrahydrofolate reductase.  Nat Genet. 1995;  10 111-113
    CrossrefPubMedGoogle Scholar
  • 3 Jacques P F, Bostom A G, Williams R R et al.. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.  Circulation. 1996;  93 7-9
    CrossrefPubMedGoogle Scholar
  • 4 Molloy A M, Daly S, Mills J L et al.. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations.  Lancet. 1997;  349 1591-1593
    CrossrefPubMedGoogle Scholar
  • 5 Weir D G, Scott J M. Homocysteine as a risk factor for cardiovascular and related disease: nutritional implications.  Nutrition Research Reviews. 1998;  11 311-338
    PubMedGoogle Scholar
  • 6 Boushey C J, Beresford S A, Omenn G S, Motulsky A G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease.  JAMA. 1995;  274 1049-1057
    Google Scholar
  • 7 Eikelboom J W, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiological evidence.  Ann Intern Med. 1999;  131 363-375
    PubMedGoogle Scholar
  • 8 Ueland P M, Refsum H, Stabler S P, Malinow M R, Anderson A, Allen R H. Total homocysteine in plasma or serum: methods and clinical applications.  Clin Chem. 1993;  39 1764-1779
    PubMedGoogle Scholar
  • 9 Cotter A M, Daly S F. Neural tube defects: is a decreasing prevalence associated with a decrease in severity?.  Eur J Obstet Gynecol Reprod Biol. 2005;  119 161-163
    CrossrefPubMedGoogle Scholar
  • 10 Botto L D, Moore C A, Khoury M J, Erickson J D. Neural-tube defects.  N Engl J Med. 1999;  341 1509-1519
    CrossrefPubMedGoogle Scholar
  • 11 MRC Vitamin Study Research Group . Prevention of neural tube defects: results of the Medical Research Council Vitamin Study.  Lancet. 1991;  338 131-137
    CrossrefPubMedGoogle Scholar
  • 12 Czeizel A E, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation.  N Engl J Med. 1992;  327 1832-1835
    PubMedGoogle Scholar
  • 13 Rothenberg S P, da Costa M P, Sequeira J M et al.. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect.  N Engl J Med. 2004;  350 134-142
    CrossrefPubMedGoogle Scholar
  • 14 Forrest J D. Epidemiology of unintended pregnancy and contraceptive use.  Am J Obstet Gynecol. 1994;  170 1485-1489
    CrossrefPubMedGoogle Scholar
  • 15 Higgins M, Daly S F. Poor compliance with folic acid supplementation recommendations among women in Dublin. Proceedings of the Irish Perinatal Society Spring Meeting 2004
    Google Scholar
  • 16 United States Food and Drug Administration . Food Standards: amendment of standards of identity for enriched grain products to require addition of folic acid.  Fed Regist. 1996;  61 8781-8797
    PubMedGoogle Scholar
  • 17 Honein M A, Paulozzi L J, Mathews T J, Erickson J D, Wong L Y. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects.  JAMA. 2001;  285 2981-2986
    CrossrefPubMedGoogle Scholar
  • 18 Persad V L, Van den Hof M C, Dube J M, Zimmer P. Incidence of open neural tube defects in Nova Scotia after folic acid fortification.  CMAJ. 2002;  167 241-245
    PubMedGoogle Scholar
  • 19 Committee on Medical Aspects of Food and Nutrition Policy (COMA) Report on Health and Social Subjects .50: Folic acid and the prevention of disease. London; The Stationery Office 2000
    Google Scholar
  • 20 Mills J L, McPartlin J M, Kirke P N et al.. Homocysteine metabolism in pregnancies complicated by neural-tube defects.  Lancet. 1995;  345 149-151
    CrossrefPubMedGoogle Scholar
  • 21 Essien F B, Wannberg L S. Methionine but not folic acid or Vitamin B-12 altered the frequency of neural tube defects in axd mutant mice.  J Nutr. 1993;  123 27-34
    PubMedGoogle Scholar
  • 22 Coelho C N, Weber J A, Klein N W, Daniels W G, Hoagland T A. Whole rat embryos require methionine for neural tube closure when cultured on cow serum.  J Nutr. 1989;  119 1716-1725
    PubMedGoogle Scholar
  • 23 Saxen I. Associations between oral clefts and drugs taken during pregnancy.  Int J Epidemiol. 1975;  4 37-44
    PubMedGoogle Scholar
  • 24 Hill L, Murphy M, McDowall M, Paul A H. Maternal drug histories and congenital malformations: limb reduction defects and oral clefts.  J Epidemiol Community Health. 1988;  42 1-7
    PubMedGoogle Scholar
  • 25 Hayes C, Werler M M, Willett W C, Mitchell A A. Case-control study of periconceptional folic acid supplementation and oral clefts.  Am J Epidemiol. 1996;  143 1229-1234
    PubMedGoogle Scholar
  • 26 Czeizel A E, Timar L, Sarkozi A. Dose-dependent effect of folic acid on the prevention of orofacial clefts.  Pediatrics. 1999;  104 e66
    CrossrefPubMedGoogle Scholar
  • 27 Kallen B. Maternal drug use and infant cleft lip/palate with special reference to corticoids.  Cleft Palate Craniofac J. 2003;  40 624-628
    PubMedGoogle Scholar
  • 28 Shaw G M, Lammer E J, Wasserman C R, O'Malley C D, Tolarova M M. Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally.  Lancet. 1995;  346 393-396
    CrossrefPubMedGoogle Scholar
  • 29 Itikala P R, Watkins M L, Mulinare J, Moore C A, Liu Y. Maternal multivitamin use and orofacial clefts in offspring.  Teratology. 2001;  63 79-86
    CrossrefPubMedGoogle Scholar
  • 30 Loffredo L C, Souza J M, Freitas J A, Mossey P A. Oral clefts and vitamin supplementation.  Cleft Palate Craniofac J. 2001;  38 76-83
    PubMedGoogle Scholar
  • 31 Werler M M, Hayes C, Louik C, Shapiro S, Mitchell A A. Multivitamin supplementation and risk of birth defects.  Am J Epidemiol. 1999;  150 675-682
    PubMedGoogle Scholar
  • 32 Czeizel A E, Toth M, Rockenbauer M. Population-based case control study of folic acid supplementation during pregnancy.  Teratology. 1996;  53 345-351
    CrossrefPubMedGoogle Scholar
  • 33 Peer L, Gordon H W, Bernhard W G. Effects of vitamins on human teratology.  Plast Reconstr Surg. 1964;  34 358-361
    PubMedGoogle Scholar
  • 34 Tolarova M, Harris J. Reduced recurrence of orofacial clefts after periconceptional supplementation with high-dose folic acid and multivitamins.  Teratology. 1995;  51 71-78
    CrossrefPubMedGoogle Scholar
  • 35 Ray J G, Meier C, Vermeulen M J, Wyatt P R, Cole D E. Association between folic acid food fortification and congenital orofacial clefts.  J Pediatr. 2003;  143 805-807
    CrossrefPubMedGoogle Scholar
  • 36 van Rooij I A, Swinkels D W, Blom H J, Merkus H M, Steegers-Theunissen R P. Vitamin and homocysteine status of mothers and infants and the risk of nonsyndromic orofacial clefts.  Am J Obstet Gynecol. 2003;  189 1155-1160
    CrossrefPubMedGoogle Scholar
  • 37 Shaw G M, Rozen R, Finnell R H, Todoroff K, Lammer E J. Infant C677T mutation in MTHFR, maternal periconceptional vitamin use, and cleft lip.  Am J Med Genet. 1998;  80 196-198
    CrossrefPubMedGoogle Scholar
  • 38 Shaw G M, Todoroff K, Finnell R H, Rozen R, Lammer E J. Maternal vitamin use, infant C677T mutation in MTHFR, and isolated cleft palate risk.  Am J Med Genet. 1999;  85 84-85
    CrossrefPubMedGoogle Scholar
  • 39 Mills J L, Kirke P N, Molloy A M et al.. Methylenetetrahydrofolate reductase thermolabile variant and oral clefts.  Am J Med Genet. 1999;  86 71-74
    CrossrefPubMedGoogle Scholar
  • 40 Jugessur A, Wilcox A J, Lie R T et al.. Exploring the effects of methylenetetrahydrofolate reductase gene variants C677T and A1298C on the risk of orofacial clefts in 261 Norwegian case-parent triads.  Am J Epidemiol. 2003;  157 1083-1091
    CrossrefPubMedGoogle Scholar
  • 41 Martinelli M, Scapoli L, Pezzetti F et al.. C677T variant form at the MTHFR gene and CL/P: a risk factor for mothers?.  Am J Med Genet. 2001;  98 357-360
    CrossrefPubMedGoogle Scholar
  • 42 Prescott N J, Winter R M, Malcolm S. Maternal MTHFR genotype contributes to the risk of non-syndromic cleft lip and palate.  J Med Genet. 2002;  39 368-369
    CrossrefPubMedGoogle Scholar
  • 43 Jugessur A, Lie R T, Wilcox A J et al.. Cleft palate, transforming growth factor alpha gene variants, and maternal exposures: assessing gene-environment interactions in case-parent triads.  Genet Epidemiol. 2003;  25 367-374
    CrossrefPubMedGoogle Scholar
  • 44 Little J, Cardy A, Munger R G. Tobacco smoking and oral clefts: a meta-analysis.  Bull World Health Organ. 2004;  82 213-218
    PubMedGoogle Scholar
  • 45 Shaw G M, Wasserman C R, O'Malley C D, Nelson V, Jackson R J. Maternal pesticide exposure from multiple sources and selected congenital anomalies.  Epidemiology. 1999;  10 60-66
    PubMedGoogle Scholar
  • 46 Marazita M L, Mooney M P. Current concepts in the embryology and genetics of cleft lip and cleft palate.  Clin Plast Surg. 2004;  31 125-140
    CrossrefPubMedGoogle Scholar
  • 47 Rosenquist T H, Ratashak S A, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid.  Proc Natl Acad Sci U S A. 1996;  93 15227-15232
    CrossrefPubMedGoogle Scholar
  • 48 Burgoon J M, Selhub J, Nadeau M, Sadler T W. Investigation of the effects of folate deficiency on embryonic development through the establishment of a folate deficient mouse model.  Teratology. 2002;  65 219-227
    CrossrefPubMedGoogle Scholar
  • 49 Junker R, Kotthoff S, Vielhaber H et al.. Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease.  Cardiovasc Res. 2001;  51 251-254
    CrossrefPubMedGoogle Scholar
  • 50 Wenstrom K D, Johanning G L, Johnston K E, DuBard M. Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations.  Am J Obstet Gynecol. 2001;  184 806-812
    CrossrefPubMedGoogle Scholar
  • 51 Shaw G M, Zhu H, Lammer E J, Yang W, Finnell R H. Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial and conotruncal heart defects.  Am J Epidemiol. 2003;  158 747-752
    CrossrefPubMedGoogle Scholar
  • 52 Storti S, Vittorini S, Lascone M R et al.. Association between 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and conotruncal heart defects.  Clin Chem Lab Med. 2003;  41 276-280
    CrossrefPubMedGoogle Scholar
  • 53 Botto L D, Olney R S, Erickson J D. Vitamin supplements and the risk for congenital anomalies other than neural tube defects.  Am J Med Genet C Semin Med Genet. 2004;  125C(1) 12-21
    CrossrefPubMedGoogle Scholar
  • 54 Czeizel A E, Dobo M, Vargha P. Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities.  Birth Defects Res A Clin Mol Teratol. 2004;  70 853-861
    PubMedGoogle Scholar
  • 55 Botto L D, Mulinare J, Erickson J D. Occurrence of congenital heart defects in relation to maternal multivitamin use.  Am J Epidemiol. 2000;  151 878-884
    PubMedGoogle Scholar
  • 56 Botto L D, Khoury M J, Mulinare J, Erickson J D. Periconceptional multivitamin use and the occurrence of conotruncal heart defects: results from a population-based, case-control study.  Pediatrics. 1996;  98 911-917
    PubMedGoogle Scholar
  • 57 Ness R B, Roberts J M. Heterogenous causes constituting the single syndrome of pre-eclampsia: A hypothesis and its implications.  Am J Obstet Gynecol. 1996;  175 1365-1370
    CrossrefPubMedGoogle Scholar
  • 58 Godfrey K M, Barker D J. Fetal nutrition and adult disease.  Am J Clin Nutr. 2000;  71 1344S-1352S
    PubMedGoogle Scholar
  • 59 Smith G CS, Pell J P, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births.  Lancet. 2001;  357 2002-2006
    CrossrefPubMedGoogle Scholar
  • 60 Irgens H U, Reisaeter L, Irgens L M, Lie R T. Long-term mortality of mothers and fathers after preeclampsia: population based cohort study.  BMJ. 2001;  323 1213-1217
    CrossrefPubMedGoogle Scholar
  • 61 Funai E F, Friedlander Y, Paltiel O et al.. Long-term mortality after preeclampsia.  Am J Obstet Gynecol. 2002;  187 S54
    PubMedGoogle Scholar
  • 62 Laivuori H, Kaaja R, Turpeinen U, Viinikka L, Ylikorkala O. Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia.  Obstet Gynecol. 1999;  93 489-493
    CrossrefPubMedGoogle Scholar
  • 63 Chambers J C, McGregor A, Jean-Marie J, Kooner J S. Acute hyperhomocysteinaemia and endothelial dysfunction.  Lancet. 1998;  351 36-37
    PubMedGoogle Scholar
  • 64 Dekker G A, de Vries J IP, Doelitzsch P M et al.. Underlying disorders associated with severe early-onset preeclampsia.  Am J Obstet Gynecol. 1995;  173 1042-1048
    CrossrefPubMedGoogle Scholar
  • 65 Hubel C A, Snaedal S, Ness R B et al.. Dyslipoproteinaemia in postmenopausal women with a history of eclampsia.  BJOG. 2000;  107 776-784
    PubMedGoogle Scholar
  • 66 Hankey G J, Eikelboom J W. Homocysteine and vascular disease.  Lancet. 1999;  354 407-413
    CrossrefPubMedGoogle Scholar
  • 67 Weir D G, Scott J M. Homocysteine as a risk factor for cardiovascular and related disease: nutritional implications.  Nutrition Research Reviews. 1998;  11 311-338
    PubMedGoogle Scholar
  • 68 Bellamy M F, McDowell I F. Putative mechanisms for vascular damage by homocysteine.  J Inherit Metab Dis. 1997;  20 307-315
    CrossrefPubMedGoogle Scholar
  • 69 Roberts J M, Redman C WG. Preeclampsia: more than pregnancy-induced hypertension.  Lancet. 1993;  341 1447-1451
    CrossrefPubMedGoogle Scholar
  • 70 Ashworth J R, Warren A Y, Johnson I R, Baker P N. Plasma from preeclamptic women and functional change in myometrial resistance arteries.  Br J Obstet Gynaecol. 1998;  105 459-461
    PubMedGoogle Scholar
  • 71 Rajkovic A, Catalano P M, Malinow M R. Elevated homocysteine levels with preeclampsia.  Obstet Gynecol. 1997;  90 168-171
    CrossrefPubMedGoogle Scholar
  • 72 Rajkovic A, Mahomed K, Malinow M R, Sorensen T K, Woelk G B, Williams M A. Plasma homocysteine concentrations in eclamptic and preeclamptic African women postpartum.  Obstet Gynecol. 1999;  94 355-360
    CrossrefPubMedGoogle Scholar
  • 73 Powers R W, Evans R W, Majors A K et al.. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation.  Am J Obstet Gynecol. 1998;  179 1605-1611
    PubMedGoogle Scholar
  • 74 Murphy M M, Scott J M, McPartlin J M, Fernandez-Ballart J D. The pregnancy related decrease in fasting plasma homocysteine is not explained by folic supplementation, hemodilution or a decrease in albumin in a longitudinal study.  Am J Clin Nutr. 2002;  76 614-619
    PubMedGoogle Scholar
  • 75 Cotter A M, Molloy A M, Scott J M, Daly S F. Elevated plasma homocysteine in early pregnancy: A risk factor for the development of severe preeclampsia.  Am J Obstet Gynecol. 2001;  185 781-785
    CrossrefPubMedGoogle Scholar
  • 76 Cotter A M, Molloy A M, Scott J M, Daly S F. Elevated plasma homocysteine in early pregnancy: A risk factor for the development of nonsevere preeclampsia.  Am J Obstet Gynecol. 2003;  189 391-394
    CrossrefPubMedGoogle Scholar
  • 77 Powers R W, Majors A K, Kerchner L J, Conrad K P. Renal handling of homocysteine during normal pregnancy and preeclampsia.  J Soc Gynecol Investig. 2004;  11 45-50
    PubMedGoogle Scholar
  • 78 Grandone E, Margaglione M, Colaizzo D et al.. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia.  Thromb Haemost. 1997;  77 1052-1054
    PubMedGoogle Scholar
  • 79 Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T. Methylenetetrahydrofolate reductase polymorphism and preeclampsia.  J Med Genet. 1997;  34 525-526
    PubMedGoogle Scholar
  • 80 Powers R W, Minich L A, Lykins D L, Ness R B, Crombleholme W R, Roberts J M. Methylenetetrahydrofolate reductase polymorphism, folate and susceptibility to preeclampsia.  J Soc Gynecol Investig. 1999;  6 74-79
    CrossrefPubMedGoogle Scholar
  • 81 Prasmusinto D, Skrablin S, Hofstaetter C, Fimmers R, van der Ven K. The methylenetetrahydrofolate reductase 677C→T polymorphism and preeclampsia in two populations.  Obstet Gynecol. 2002;  99 1085-1092
    CrossrefPubMedGoogle Scholar
  • 82 Powers R W, Dunbar M S, Gallaher M J, Roberts J M. The 677 C-T methylenetetrahydrofolate reductase mutation does not predict increased maternal homocysteine during pregnancy.  Obstet Gynecol. 2003;  101 762-766
    CrossrefPubMedGoogle Scholar
  • 83 Vollset S E, Refsum H, Irgens L M et al.. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland homocysteine study.  Am J Clin Nutr. 2000;  71 962-968
    PubMedGoogle Scholar
  • 84 Powers R W, Gandley R E, Lykins D L, Roberts J M. Moderate hyperhomocysteinemia decreases endothelial dependent vasorelaxation in pregnant but not non-pregnant mice.  Hypertension. 2004;  44 327-333
    CrossrefPubMedGoogle Scholar
  • 85 Goddijn-Wessel T A, Wouters M G, van de Molen E F et al.. Hyperhomocysteinaemia: a risk factor for placental abruption or infarction.  Eur J Obstet Gynecol Reprod Biol. 1996;  66 23-29
    CrossrefPubMedGoogle Scholar
  • 86 Steegers-Theunissen R PM, Boers G HJ, Blom H J, Trijbels F JM, Eskes T KAB. Hyperhomocysteinaemia and recurrent spontaneous abortion or abruptio placentae.  Lancet. 1992;  339 1122-1123
    PubMedGoogle Scholar
  • 87 de Vries J IP, Dekker G A, Huijgens P C, Jakobs C, Blomberg B, van Geijn H P. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies.  Br J Obstet Gynaecol. 1997;  104 1248-1254
    CrossrefPubMedGoogle Scholar
  • 88 Scholl T O, Johnson W G. Folic acid: influence on the outcome of pregnancy.  Am J Clin Nutr. 2000;  71 1295S-1303S
    PubMedGoogle Scholar
  • 89 de Weerd S, Steegers-Theunissen R P, de Boo T M, Thomas C M, Steegers E A. Maternal periconceptual biochemical and hematological parameters, vitamin profiles and pregnancy oucome.  Eur J Clin Nutr. 2003;  57 1128-1134
    CrossrefPubMedGoogle Scholar
  • 90 Hibbard B M. The role of folic acid in pregnancy with particular reference to anaemia, abruption and abortion.  J Obstet Gynaecol Br Commonw. 1964;  71 529-542
    PubMedGoogle Scholar
  • 91 Mudd S H, Skovby F, Levy H L et al.. The natural history of homocystinuria due to cystathionine β synthase deficiency.  Am J Hum Genet. 1985;  37 1-31
    PubMedGoogle Scholar
  • 92 Wouters M G, Boers G H, Blom H J et al.. Hyperhomocysteinaemia; a risk factor in women with unexplained recurrent early pregnancy loss.  Fertil Steril. 1993;  60 820-825
    PubMedGoogle Scholar
  • 93 Nelen W L, Bulten J, Steegers E A, Blom H J, Hanselaar A G, Eskes T K. Maternal homocysteine and chorionic vascularization in recurrent early pregnancy loss.  Hum Reprod. 2000;  15 954-960
    CrossrefPubMedGoogle Scholar
  • 94 Nelen W L, Steegers E A, Eskes T K, Blom H J. Genetic risk factor for unexplained recurrent early pregnancy loss.  Lancet. 1997;  350 861
    PubMedGoogle Scholar
  • 95 Hogge W A, Byrnes A L, Lanasa M C, Surti U. The clinical use of karyotyping spontaneous abortions.  Am J Obstet Gynecol. 2003;  189 397-400
    CrossrefPubMedGoogle Scholar
  • 96 Roque H, Paidas M J, Funai E F, Kuczynski E, Lockwood C J. Maternal thrombophilias are not associated with early pregnancy loss.  Thromb Haemost. 2004;  91 290-295
    PubMedGoogle Scholar
  • 97 Murphy M M, Scott J M, Arija V, Molloy A M, Fernandez-Ballart J D. Maternal homocysteine before conception and throughout pregnancy predicts fetal homocysteine and birth weight.  Clin Chem. 2004;  50 1406-1412
    CrossrefPubMedGoogle Scholar
  • 98 Rolschau J, Kristoffersen K, Ulrich M, Grinsted P, Schaumberg E, Foged N. The influence of folic acid supplements on the outcome of pregnancies in the county of Funen in Denmark.  Eur J Obstet Gynecol Reprod Biol. 1999;  87 105-110
    CrossrefPubMedGoogle Scholar
  • 99 Infante-Rivard C, Rivard G E, Gauthier R, Theoret Y. Unexpected relationship between plasma homocysteine and intrauterine growth restriction.  Clin Chem. 2003;  49 1476-1482
    PubMedGoogle Scholar
  • 100 van der Molen E F, Verbruggen B, Novakova I, Eskes T K, Monnens L A, Blom H J. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy.  BJOG. 2000;  107 785-791
    CrossrefPubMedGoogle Scholar
  • 101 Wang J, Trudinger B J, Duarte N, Wilcken D E, Wang X L. Elevated circulating homocysteine levels in placental vascular disease and associated preeclampsia.  BJOG. 2000;  107 935-938
    PubMedGoogle Scholar

 Dr.
Sean Daly

Coombe Women's Hospital

Dublin 8, Ireland

      >